Bundamedik Tbk PT (BMHS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bundamedik Tbk PT (BMHS) has a cash flow conversion efficiency ratio of 0.083x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp199.64 Billion ≈ $11.70 Million USD) by net assets (Rp2.39 Trillion ≈ $140.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bundamedik Tbk PT balance sheet independence to measure how much of total assets are equity-financed.
Bundamedik Tbk PT - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bundamedik Tbk PT's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bundamedik Tbk PT (BMHS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Bundamedik Tbk PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bundamedik Tbk PT ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Galleon Gold Corp
V:GGO
|
-0.008x |
|
LBG MEDIA PLC LS -001
F:S83
|
0.059x |
|
China Silver Group Limited
F:2CS
|
0.013x |
|
Yirendai Ltd
NYSE:YRD
|
-0.001x |
|
AKA Brands Holding Corp
NYSE:AKA
|
-0.041x |
|
Technical Olympic S.A
AT:OLYMP
|
-0.002x |
|
PT Surya Pertiwi Tbk
JK:SPTO
|
0.021x |
|
Unique Engineering and Construction Public Company Limited
BK:UNIQ
|
0.005x |
Annual Cash Flow Conversion Efficiency for Bundamedik Tbk PT (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bundamedik Tbk PT from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Bundamedik Tbk PT (BMHS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Rp2.39 Trillion ≈ $140.31 Million |
Rp250.62 Billion ≈ $14.69 Million |
0.105x | +561.56% |
| 2024-12-31 | Rp2.15 Trillion ≈ $125.85 Million |
Rp33.98 Billion ≈ $1.99 Million |
0.016x | -44.64% |
| 2023-12-31 | Rp1.80 Trillion ≈ $105.47 Million |
Rp51.44 Billion ≈ $3.01 Million |
0.029x | -78.24% |
| 2022-12-31 | Rp1.81 Trillion ≈ $105.96 Million |
Rp237.47 Billion ≈ $13.91 Million |
0.131x | -36.61% |
| 2021-12-31 | Rp1.69 Trillion ≈ $98.84 Million |
Rp349.44 Billion ≈ $20.48 Million |
0.207x | +14.24% |
| 2020-12-31 | Rp1.05 Trillion ≈ $61.51 Million |
Rp190.36 Billion ≈ $11.15 Million |
0.181x | +34.54% |
| 2019-12-31 | Rp665.59 Billion ≈ $39.00 Million |
Rp89.72 Billion ≈ $5.26 Million |
0.135x | +63.82% |
| 2018-12-31 | Rp532.23 Billion ≈ $31.19 Million |
Rp43.79 Billion ≈ $2.57 Million |
0.082x | -- |
About Bundamedik Tbk PT
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, and dental clinic services management consulting businesses. It also provides ferti… Read more